Search

Introduction: To analyze, using bibliometric techniques, the scientific production on drug-related problem (DRP) indexed in the Scopus bibliographic database. Method: Cross-sectional descriptive study. Data were obtained from the Scopus database, querying with the term “drug-related problem” in the registration fields of title, abstract and keywords; final search date January 2024. Results: A total of 2992 references were obtained. The annual relationship of the number of publications showed a direct linear regression model (R2 = 0.8; p < 0.001). The most frequent document type was the original article with 2455 (82.1%) references, with a productivity index of 3.4. Papers published in 26 different languages were identified, with English being the predominant language with 2607 (87.1%) papers. There was a statistically significant correlation between JCR and CiteScore impact indicators (R = 0.7, p = 0.005). A total of 40659 keywords (KW) were found, with an average of 13.6 KW per paper. The most used KW was Human, in 2411 (5.9%) times. Conclusions: Taking into account all previously mentioned, it could be concluded: This study showed that research in the field of DRPs has experienced a steady growth over the years, although it has not yet reached exponential growth. The original article was the most common type of document in scientific production. There was a clear Anglo-Saxon influence, both in terms of language and institutional affiliation. The lack of use of standardized language was evident. [ABSTRACT FROM AUTHOR]

Treatment with interferon beta (IFNβ) is one of the first-line treatments for multiple sclerosis. In clinical practice, however, many patients present suboptimal response to IFNβ, with the proportion of non-responders ranging from 20 to 50%. This variable response can be affected by genetic factors, such as polymorphisms in the genes involved in the disease state, pharmacodynamics, metabolism or in the action mechanism of IFNβ, which can affect the efficacy of this drug. This review assesses the impact of pharmacogenetics studies on response to IFNβ treatment among patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). The results suggest that the detection of polymorphisms in several genes (CD46, CD58, FHIT, IRF5, GAPVD1, GPC5, GRBRB3, MxA, PELI3 and ZNF697) could be used in the future as predictive markers of response to IFNβ treatment in patients diagnosed with RRMS. However, few studies have been carried out and they have been performed on small sample sizes, which makes it difficult to generalize the role of these genes in IFNβ treatment. Studies on large sample sizes with longer term follow-up are therefore required to confirm these results., Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)